Beijing Med-Pharm Inks Deal With KV Pharmaceutical To Bring Clindesse To China
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing and distribution firm will be responsible for completing late-stage clinical development and registration of clindamycin.
You may also be interested in...
Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 1 of 2)
Exec discusses the firm’s business model, how distribution figures into the equation, and how Beijing Med-Pharm is broadening its reach into key Chinese markets.
Cephalon Inks Deal To Market Fentora In China
Beijing Med-Pharm will carry out the clinical development and registration process for select Cephalon products, starting with the Actiq follow on.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.